This is a rare type of cancer that starts in the muscles of the stomach or intestines. It's a tumor that grows in the wall of the digestive tract. Doctors often call it a Gastrointestinal Stromal Neoplasm or Tumor.
Every report comes from a Lived member, sent anonymously.
Have you tried Gleevec (Imatinib) for Gastrointestinal Stromal Tumor?
A gastrointestinal stromal tumor (GIST) is a tumor that grows from the wall of the digestive tract rather than from its inner lining, where most stomach and colon cancers start. About 60% begin in the stomach and about 30% in the small intestine, though a GIST can appear anywhere along the digestive tract. GISTs are uncommon, with over 6,000 new cases a year in the United States, and are diagnosed most often in people in their 60s. GISTs vary widely in behavior. Some stay small and slow-growing and may never cause a problem, while others grow quickly and spread, most often to the liver or the lining of the abdomen. Because they grow within the wall of the gut, they may cause no symptoms for a long time. When they do, the most common sign is bleeding into the digestive tract, which can show up as blood in vomit or stool, or slowly as anemia (a low red blood cell count) that causes tiredness. Others notice belly pain, feeling full after only a little food, or trouble swallowing.
Most GISTs are sporadic, meaning they arise from a genetic change that happens in the tumor cells during a person's life rather than one that is inherited. In about 80% of GISTs, the change is in a gene called KIT; in a smaller share, it is in a related gene called PDGFRA. Both genes help control cell growth, and the change leaves a growth signal switched on. No lifestyle or dietary cause has been established. A small number of GISTs are linked to inherited conditions, including neurofibromatosis type 1 (NF1) and rare syndromes involving the SDH genes, such as Carney-Stratakis syndrome. These forms tend to appear at younger ages and may involve several tumors. GIST in children and young adults is rare and is nearly always connected to an underlying genetic predisposition, so a young diagnosis is often a reason to discuss genetic counseling.
A GIST is often found during a scan or endoscopy for another reason, or while investigating bleeding, anemia or belly symptoms. A CT or MRI scan shows the tumor's size and location and whether it has spread. For tumors in the upper digestive tract, an endoscopic ultrasound, in which a thin camera tube with an ultrasound probe is passed through the mouth, can show the tumor beneath the lining and guide a needle biopsy. Doctors generally prefer this route to a needle through the skin, because puncturing the tumor from outside carries a risk of bleeding and spread. When a tumor looks typical and can be removed easily, some surgeons operate without a biopsy first. A pathologist confirms the diagnosis with stains for markers such as KIT (also called CD117) and DOG1, which help tell GIST apart from other tumors of the gut wall. Two further results shape treatment. The mitotic rate is a count of how many cells are dividing; together with tumor size and location, it estimates the risk of the tumor coming back after surgery. Molecular testing identifies which gene change the tumor carries, which matters because medicines work differently against different changes. For example, a PDGFRA change called D842V does not respond to the standard first medicine, and GISTs without KIT or PDGFRA changes respond poorly to this whole class of drugs.
Surgery is the main treatment for a GIST that has not spread. Tumors 2 cm or larger are usually removed, along with a margin of normal tissue, sometimes through small keyhole incisions (laparoscopy). GISTs rarely spread to lymph nodes, so extensive lymph node removal is usually not needed. For small tumors under 2 cm found by chance, doctors do not agree on whether to remove them or watch them with repeat scans. The key medicines are tyrosine kinase inhibitors (TKIs), daily targeted pills that block the overactive growth signal driving most GISTs. Imatinib (Gleevec) is the first choice for most people. After surgery, people whose tumor carries a high risk of returning are usually offered imatinib for at least three years, since three years lowered recurrence and improved survival compared with one year in a major trial. For a tumor too large or awkwardly placed to remove safely, imatinib can shrink it first so surgery becomes possible. For GIST that has spread or returned, imatinib is usually continued long term for as long as it keeps the disease under control and side effects are manageable. The tumor's gene change shapes these choices. Tumors with the PDGFRA D842V change are treated with avapritinib (Ayvakit) instead of imatinib, and some KIT changes call for a higher imatinib dose. If imatinib stops working, other TKIs (sunitinib, then regorafenib, then ripretinib) can be tried in sequence, though each tends to control the disease for a shorter time. Common imatinib side effects include puffiness around the eyes or swelling of the legs, diarrhea, nausea, tiredness and muscle cramps, and they often ease over time. Imatinib also interacts with some other medicines, so the care team should know everything you take. Clinical trials are an important option, particularly for tumors that resist standard drugs.
The outlook depends largely on the tumor's size, location, mitotic rate and whether it can be completely removed. Many people with a small, low-risk GIST are treated with surgery alone and then followed with periodic scans. People with higher-risk tumors usually spend several years on imatinib after surgery, and those with spread or recurrent disease often live with GIST as a long-term condition managed with daily medicine, sometimes for many years. Imatinib appears to hold GIST in check rather than eliminate every cell. In a major trial, recurrences rose within 6 to 12 months after people stopped taking it, which is why stopping or pausing the medicine should be a planned decision with the oncologist, not something done on your own. Follow-up typically means CT or MRI scans of the abdomen and pelvis every 3 to 6 months in the early years for many people, less often for very low-risk tumors, plus regular checks on side effects and blood counts. Because GIST is rare, many people are treated at or in consultation with a center that sees sarcomas regularly.
See a doctor if you have ongoing belly pain, feel full after eating very little, have trouble swallowing, unexplained tiredness or a lump in your abdomen, or notice small amounts of blood in your stool. If you are being treated for GIST, contact your care team about new or worsening symptoms, swelling or weight gain from fluid, or side effects that make it hard to keep taking your medicine. Bleeding is the most common serious problem with GIST. Call 911 or go to the nearest emergency room if you vomit blood or material that looks like coffee grounds, have black, tarry stools or a lot of blood in your stool, feel lightheaded or dizzy from bleeding, or have severe abdominal pain along with bleeding.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Gastrointestinal Stromal Tumor is like, what's helped you, or ask the community a question.